| Literature DB >> 27236920 |
Stephen R F Twigg1, Robert B Hufnagel2, Kerry A Miller1, Yan Zhou1, Simon J McGowan3, John Taylor4, Jude Craft5, Jenny C Taylor6, Stephanie L Santoro2, Taosheng Huang2, Robert J Hopkin2, Angela F Brady7, Jill Clayton-Smith8, Carol L Clericuzio9, Dorothy K Grange10, Leopold Groesser11, Christian Hafner11, Denise Horn12, I Karen Temple13, William B Dobyns14, Cynthia J Curry15, Marilyn C Jones16, Andrew O M Wilkie17.
Abstract
Curry-Jones syndrome (CJS) is a multisystem disorder characterized by patchy skin lesions, polysyndactyly, diverse cerebral malformations, unicoronal craniosynostosis, iris colobomas, microphthalmia, and intestinal malrotation with myofibromas or hamartomas. Cerebellar medulloblastoma has been described in a single affected individual; in another, biopsy of skin lesions showed features of trichoblastoma. The combination of asymmetric clinical features, patchy skin manifestations, and neoplastic association previously led to the suggestion that this could be a mosaic condition, possibly involving hedgehog (Hh) signaling. Here, we show that CJS is caused by recurrent somatic mosaicism for a nonsynonymous variant in SMO (c.1234C>T [p.Leu412Phe]), encoding smoothened (SMO), a G-protein-coupled receptor that transduces Hh signaling. We identified eight mutation-positive individuals (two of whom had not been reported previously) with highly similar phenotypes and demonstrated varying amounts of the mutant allele in different tissues. We present detailed findings from brain MRI in three mutation-positive individuals. Somatic SMO mutations that result in constitutive activation have been described in several tumors, including medulloblastoma, ameloblastoma, and basal cell carcinoma. Strikingly, the most common of these mutations is the identical nonsynonymous variant encoding p.Leu412Phe. Furthermore, this substitution has been shown to activate SMO in the absence of Hh signaling, providing an explanation for tumor development in CJS. This raises therapeutic possibilities for using recently generated Hh-pathway inhibitors. In summary, our work uncovers the major genetic cause of CJS and illustrates strategies for gene discovery in the context of low-level tissue-specific somatic mosaicism.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27236920 PMCID: PMC4908219 DOI: 10.1016/j.ajhg.2016.04.007
Source DB: PubMed Journal: Am J Hum Genet ISSN: 0002-9297 Impact factor: 11.025